clinical trial · NCT06669117
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Pierre Fabre Medicament·phase2·recruiting·n = 140
Solid TumorMET AlterationVERT-002
brief summary
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
started
Oct 22, 2024
primary completion
Oct 21, 2030
completion
Oct 1, 2032
last updated
Jul 2, 2025
official title
A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol